Characterization and outcome of "hard to mobilize" lymphoma patients undergoing autologous stem cell transplantation

M. W. Sugrue, K. Williams, Bradley H Pollock, S. Khan, S. Peracha, J. R. Wingrad, J. S. Moreb

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

A "hard to mobilize" patient was defined as one in whom ≥ 1×106CD 34+ cells/kg cannot be obtained after two consecutive large volume aphereses. Forty-four consecutive Hodgkin's and non-Hodgkin's lymphoma patients who underwent autologous peripheral blood stem cell (PBSC) transplant treatment between June 1996 and June 1998 were included in this study. Twenty-one patients (48%) met the definition of "hard to mobilize" (Group I). All the rest of the patients (n=23) were the good mobilizers (Group II). The initial mobilization protocol for most patients was 10 μg/kg of G-CSF alone for both groups. For Group I, 7/21 (33%) patients were unable to achieve a minimal dose of ≥ 1×106 CD34+ cells/kg even after a second mobilization attempt and/or bone marrow (BM) harvest (n=5). Overall, 11/21 (52%) required an additional mobilization and/or BM harvest. Only 3/21 (14%) patients were able to meet the target cell dose of ≥ 2.5×106 CD34+ cells/kg (median of 4 apheresis). In contrast, 87% of Group II achieved the target dose with a median of 2 aphereses. Predictors of poor mobilization were greater than two prior treatment regimens (p=0.038) and the WBC count (<25,000/μL) on the first day of apheresis (p=0.053). Nineteen patients in Group I and all Group II completed treatment with a median time of engraftment of ANC>500/μl of 12 and 11 days, and platelet >20×103/μ1 of 31 and 13 days, respectively. Outcome analysis revealed that 6/19 patients in Group I died of relapse within one year from transplant compared with only 2/23 of Group II who died of relapse (p=0.005, log rank test). There were no treatment related deaths in either group. Independent predictive features for "hard to mobilize" patients are a lack of significant increase in WBC count on the first day of apheresis and the number of prior treatment regimens. Poor mobilization appears to predict a worse outcome after autografting for lymphoma patients.

Original languageEnglish (US)
Pages (from-to)509-519
Number of pages11
JournalLeukemia and Lymphoma
Volume39
Issue number5-6
StatePublished - 2000
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Lymphoma
Blood Component Removal
Bone Marrow
Transplants
Recurrence
Autologous Transplantation
Granulocyte Colony-Stimulating Factor
Therapeutics
Hodgkin Disease
Non-Hodgkin's Lymphoma
Blood Platelets

Keywords

  • Autologous stem cell transplantation
  • Lymphoma
  • Mobilization of stem cells

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Sugrue, M. W., Williams, K., Pollock, B. H., Khan, S., Peracha, S., Wingrad, J. R., & Moreb, J. S. (2000). Characterization and outcome of "hard to mobilize" lymphoma patients undergoing autologous stem cell transplantation. Leukemia and Lymphoma, 39(5-6), 509-519.

Characterization and outcome of "hard to mobilize" lymphoma patients undergoing autologous stem cell transplantation. / Sugrue, M. W.; Williams, K.; Pollock, Bradley H; Khan, S.; Peracha, S.; Wingrad, J. R.; Moreb, J. S.

In: Leukemia and Lymphoma, Vol. 39, No. 5-6, 2000, p. 509-519.

Research output: Contribution to journalArticle

Sugrue, MW, Williams, K, Pollock, BH, Khan, S, Peracha, S, Wingrad, JR & Moreb, JS 2000, 'Characterization and outcome of "hard to mobilize" lymphoma patients undergoing autologous stem cell transplantation', Leukemia and Lymphoma, vol. 39, no. 5-6, pp. 509-519.
Sugrue, M. W. ; Williams, K. ; Pollock, Bradley H ; Khan, S. ; Peracha, S. ; Wingrad, J. R. ; Moreb, J. S. / Characterization and outcome of "hard to mobilize" lymphoma patients undergoing autologous stem cell transplantation. In: Leukemia and Lymphoma. 2000 ; Vol. 39, No. 5-6. pp. 509-519.
@article{052eb5b854744c0db5aa44ecaee613af,
title = "Characterization and outcome of {"}hard to mobilize{"} lymphoma patients undergoing autologous stem cell transplantation",
abstract = "A {"}hard to mobilize{"} patient was defined as one in whom ≥ 1×106CD 34+ cells/kg cannot be obtained after two consecutive large volume aphereses. Forty-four consecutive Hodgkin's and non-Hodgkin's lymphoma patients who underwent autologous peripheral blood stem cell (PBSC) transplant treatment between June 1996 and June 1998 were included in this study. Twenty-one patients (48{\%}) met the definition of {"}hard to mobilize{"} (Group I). All the rest of the patients (n=23) were the good mobilizers (Group II). The initial mobilization protocol for most patients was 10 μg/kg of G-CSF alone for both groups. For Group I, 7/21 (33{\%}) patients were unable to achieve a minimal dose of ≥ 1×106 CD34+ cells/kg even after a second mobilization attempt and/or bone marrow (BM) harvest (n=5). Overall, 11/21 (52{\%}) required an additional mobilization and/or BM harvest. Only 3/21 (14{\%}) patients were able to meet the target cell dose of ≥ 2.5×106 CD34+ cells/kg (median of 4 apheresis). In contrast, 87{\%} of Group II achieved the target dose with a median of 2 aphereses. Predictors of poor mobilization were greater than two prior treatment regimens (p=0.038) and the WBC count (<25,000/μL) on the first day of apheresis (p=0.053). Nineteen patients in Group I and all Group II completed treatment with a median time of engraftment of ANC>500/μl of 12 and 11 days, and platelet >20×103/μ1 of 31 and 13 days, respectively. Outcome analysis revealed that 6/19 patients in Group I died of relapse within one year from transplant compared with only 2/23 of Group II who died of relapse (p=0.005, log rank test). There were no treatment related deaths in either group. Independent predictive features for {"}hard to mobilize{"} patients are a lack of significant increase in WBC count on the first day of apheresis and the number of prior treatment regimens. Poor mobilization appears to predict a worse outcome after autografting for lymphoma patients.",
keywords = "Autologous stem cell transplantation, Lymphoma, Mobilization of stem cells",
author = "Sugrue, {M. W.} and K. Williams and Pollock, {Bradley H} and S. Khan and S. Peracha and Wingrad, {J. R.} and Moreb, {J. S.}",
year = "2000",
language = "English (US)",
volume = "39",
pages = "509--519",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "5-6",

}

TY - JOUR

T1 - Characterization and outcome of "hard to mobilize" lymphoma patients undergoing autologous stem cell transplantation

AU - Sugrue, M. W.

AU - Williams, K.

AU - Pollock, Bradley H

AU - Khan, S.

AU - Peracha, S.

AU - Wingrad, J. R.

AU - Moreb, J. S.

PY - 2000

Y1 - 2000

N2 - A "hard to mobilize" patient was defined as one in whom ≥ 1×106CD 34+ cells/kg cannot be obtained after two consecutive large volume aphereses. Forty-four consecutive Hodgkin's and non-Hodgkin's lymphoma patients who underwent autologous peripheral blood stem cell (PBSC) transplant treatment between June 1996 and June 1998 were included in this study. Twenty-one patients (48%) met the definition of "hard to mobilize" (Group I). All the rest of the patients (n=23) were the good mobilizers (Group II). The initial mobilization protocol for most patients was 10 μg/kg of G-CSF alone for both groups. For Group I, 7/21 (33%) patients were unable to achieve a minimal dose of ≥ 1×106 CD34+ cells/kg even after a second mobilization attempt and/or bone marrow (BM) harvest (n=5). Overall, 11/21 (52%) required an additional mobilization and/or BM harvest. Only 3/21 (14%) patients were able to meet the target cell dose of ≥ 2.5×106 CD34+ cells/kg (median of 4 apheresis). In contrast, 87% of Group II achieved the target dose with a median of 2 aphereses. Predictors of poor mobilization were greater than two prior treatment regimens (p=0.038) and the WBC count (<25,000/μL) on the first day of apheresis (p=0.053). Nineteen patients in Group I and all Group II completed treatment with a median time of engraftment of ANC>500/μl of 12 and 11 days, and platelet >20×103/μ1 of 31 and 13 days, respectively. Outcome analysis revealed that 6/19 patients in Group I died of relapse within one year from transplant compared with only 2/23 of Group II who died of relapse (p=0.005, log rank test). There were no treatment related deaths in either group. Independent predictive features for "hard to mobilize" patients are a lack of significant increase in WBC count on the first day of apheresis and the number of prior treatment regimens. Poor mobilization appears to predict a worse outcome after autografting for lymphoma patients.

AB - A "hard to mobilize" patient was defined as one in whom ≥ 1×106CD 34+ cells/kg cannot be obtained after two consecutive large volume aphereses. Forty-four consecutive Hodgkin's and non-Hodgkin's lymphoma patients who underwent autologous peripheral blood stem cell (PBSC) transplant treatment between June 1996 and June 1998 were included in this study. Twenty-one patients (48%) met the definition of "hard to mobilize" (Group I). All the rest of the patients (n=23) were the good mobilizers (Group II). The initial mobilization protocol for most patients was 10 μg/kg of G-CSF alone for both groups. For Group I, 7/21 (33%) patients were unable to achieve a minimal dose of ≥ 1×106 CD34+ cells/kg even after a second mobilization attempt and/or bone marrow (BM) harvest (n=5). Overall, 11/21 (52%) required an additional mobilization and/or BM harvest. Only 3/21 (14%) patients were able to meet the target cell dose of ≥ 2.5×106 CD34+ cells/kg (median of 4 apheresis). In contrast, 87% of Group II achieved the target dose with a median of 2 aphereses. Predictors of poor mobilization were greater than two prior treatment regimens (p=0.038) and the WBC count (<25,000/μL) on the first day of apheresis (p=0.053). Nineteen patients in Group I and all Group II completed treatment with a median time of engraftment of ANC>500/μl of 12 and 11 days, and platelet >20×103/μ1 of 31 and 13 days, respectively. Outcome analysis revealed that 6/19 patients in Group I died of relapse within one year from transplant compared with only 2/23 of Group II who died of relapse (p=0.005, log rank test). There were no treatment related deaths in either group. Independent predictive features for "hard to mobilize" patients are a lack of significant increase in WBC count on the first day of apheresis and the number of prior treatment regimens. Poor mobilization appears to predict a worse outcome after autografting for lymphoma patients.

KW - Autologous stem cell transplantation

KW - Lymphoma

KW - Mobilization of stem cells

UR - http://www.scopus.com/inward/record.url?scp=0034488523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034488523&partnerID=8YFLogxK

M3 - Article

VL - 39

SP - 509

EP - 519

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 5-6

ER -